Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

23,580 signal articles · 323 in last 24h · 112,379 total before filter · latest 1h ago

323last 24h

2136last 7d

376● bullish (7d)

188● bearish (7d)

204publishers

All Macro294 Earnings1215 M&A91 Regulatory23 Product13 Analyst20

✕ clear all filtersticker: GILDsentiment: bearishSentiment:bullish neutral bearish show all (incl. clickbait)

Barrons.com97d agobearish

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut?

Gilead Sciences beat analysts’ earnings and revenue expectations in its latest quarter. Gilead logged adjusted earnings of $2.03 a share, ahead of the $1.91 consensus among analysts polled by FactSet. Gilead’s top-line growth rested heavily on Biktarvy, its blockbuster HIV treatment, which accounted for nearly half of total revenue as sales rose 8% to $3.4 billion.

GILD

Reuters97d agobearish

Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

By Deena Beasley LOS ANGELES, May 7 (Reuters) - Gilead Sciences on Thursday posted a higher-than-expected first-quarter profit and raised its outlook for 2026 sales, but said it now expects a loss for

GILD